We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Arca to Test Heart Failure Drug in Genotype Patient Subgroup
Arca to Test Heart Failure Drug in Genotype Patient Subgroup
May 21, 2010
The FDA has signed off on a special protocol assessment (SPA) agreement with Arca Biopharma that allows the company to test its investigational heart failure drug bucindolol on a genotypic subgroup of patients that responds most favorably to the compound.